CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 111 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q1 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $228,000 | +61.7% | 115,821 | +2.5% | 0.00% | – |
Q4 2020 | $141,000 | -30.5% | 113,023 | 0.0% | 0.00% | – |
Q3 2020 | $203,000 | -75.8% | 113,023 | +12.9% | 0.00% | -100.0% |
Q2 2020 | $840,000 | +60.3% | 100,065 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $524,000 | +5.0% | 100,065 | +9.5% | 0.00% | 0.0% |
Q4 2019 | $499,000 | +12.1% | 91,392 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $445,000 | -29.7% | 91,392 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $633,000 | +7.5% | 91,392 | +7.9% | 0.00% | 0.0% |
Q1 2019 | $589,000 | +29.7% | 84,711 | +9.0% | 0.00% | 0.0% |
Q4 2018 | $454,000 | -21.2% | 77,739 | +1.8% | 0.00% | 0.0% |
Q3 2018 | $576,000 | +49.2% | 76,342 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $386,000 | -15.4% | 76,342 | +2.1% | 0.00% | 0.0% |
Q1 2018 | $456,000 | -15.9% | 74,799 | -2.1% | 0.00% | 0.0% |
Q4 2017 | $542,000 | +5.7% | 76,403 | +6.5% | 0.00% | 0.0% |
Q3 2017 | $513,000 | +3.6% | 71,729 | -8.6% | 0.00% | 0.0% |
Q2 2017 | $495,000 | – | 78,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |